http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-602622-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fd47318319f20f7f99d9fef1fd3e511b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F5-025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F5-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F5-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F5-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F5-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-69 |
| filingDate | 2011-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da27a5ab909885a650d7d936ab8c6bb2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70742f27d87a6efe6bc01e27042e2177 |
| publicationDate | 2015-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-602622-A |
| titleOfInvention | Derivatives of 1-amino-2-cyclopropylethylboronic acid |
| abstract | Disclosed are ((1R)-2-cyclopropyl-1-{ [(2S)-3-phenyl-2-(amino)propanoyl]amino} ethyl)boronic acid derivatives as represented by the general formula (I), or a pharmaceutically acceptable salt or boronic acid anhydride thereof, wherein: A is 0, 1, or 2; P is hydrogen, Rc-C(O)-, Rc-O-C(O)-, Rc-N(R4c)-C(O)-, Rc-S(O)2-, or Rc-N(R4c)-S(O)2-; Z1 and Z2 are each independently hydroxy, alkoxy, aryloxy, or aralkoxy; or Z1 and Z2 together form a moiety derived from a boronic acid complexing agent; and wherein the remaining substituents are as defined herein. Representative compounds include ((1R)-2-cyclopropyl-1-{ [(2S)-3-phenyl-2-({ [4-(pyridin-2-yloxy)phenyl]sulfonyl} amino)propanoyl]amino} ethyl)boronic acid, ((1R)-2-cyclopropyl-1-{ [(2S)-3-phenyl-2-({ [4-(pyridin-3-yloxy)phenyl]sulfonyl} amino)propanoyl]amino} ethyl)boronic acid, { (1R)-2-cyclopropyl-1-[((2S)-2-{ [(6-morpholin-4-ylpyridin-3-yl)sulfonyl]amino} -3-phenylpropanoyl)amino]ethyl} boronic acid, [(1R)-1-({ (2S)-2-[(1,3-benzothiazol-6-ylsulfonyl)amino]-3-phenylpropanoyl} amino)-2-cyclopropylethyl]boronic acid, ((1R)-2-cyclopropyl-1-{ [(2S)-2-({ [3-(2-methyl-1,3-thiazol-4-yl)phenyl]sulfonyl} amino)-3-phenylpropanoyl]amino} ethyl)boronic acid, { (1R)-2-cyclopropyl-1-[((2S)-2-{ [(1-methyl-1H-indol-4-yl)sulfonyl]amino} -3-phenylpropanoyl)amino]ethyl} boronic acid, [(1R)-2-cyclopropyl-1-({ (2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl} amino)ethyl]boronic acid, ((1R)-2-cyclopropyl-1-{ [(2S)-3-phenyl-2-({ [4-(pyridin-3-ylsulfonyl)phenyl]sulfonyl} amino)propanoyl]amino} ethyl)boronic acid, ((1R)-1-{ [(2S)-2-({ [4-(1H-benzimidazol-5-yloxy)phenyl]sulfonyl} amino)-3-phenylpropanoyl]amino} -2-cyclopropylethyl)boronic acid and { (1R)-2-cyclopropyl-1-[((2S)-2-{ [(2-phenoxypyrimidin-5-yl)sulfonyl]amino} -3-phenylpropanoyl)amino]ethyl} boronic acid. Also disclosed is a pharmaceutical composition comprising a compound as defined above, and a pharmaceutically acceptable carrier or diluent, for use in treating cancer in a patient in need thereof, and preferably where the cancer is selected from the group consisting of multiple myeloma, mantle cell lymphoma, follicular lymphoma, amyloidosis, head and neck cancer, soft-tissue sarcoma, non-small cell lung cancer, and prostate cancer. |
| priorityDate | 2010-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 37.